| Drug General Information |
| Drug ID |
D0E3TC
|
| Former ID |
DNC001380
|
| Drug Name |
Staurosporine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 2 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C28H26N4O3
|
| InChI |
InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
|
| InChIKey |
HKSZLNNOFSGOKW-FYTWVXJKSA-N
|
| CAS Number |
CAS 62996-74-1
|
| PubChem Compound ID |
|
| PubChem Substance ID |
597297, 831159, 841202, 3153154, 7890617, 7890621, 8032349, 11120145, 11120633, 11121121, 11147228, 11404389, 11538020, 14760668, 22395183, 22395940, 24844236, 26755744, 26755745, 34709538, 46392655, 46392942, 46393149, 46393168, 46393293, 46393541, 46393560, 46393654, 46394044, 46394184, 47439994, 47588763, 48258965, 49681204, 49965091, 50111287, 50751691, 53789987, 57312921, 57551949, 81060920, 81061213, 81064252, 85787454, 92310109, 92473422, 99437144, 100053925, 104225349, 117393230
|
| ChEBI ID |
ChEBI:15738
|
| Target and Pathway |
| Target(s) |
Inhibitor of nuclear factor kappa B kinase beta subunit |
Target Info |
Inhibitor |
[3]
|
|---|
| Protein kinase C |
Target Info |
Inhibitor |
[4]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Chemokine signaling pathway
|
|
NF-kappa B signaling pathway
|
|
FoxO signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Apoptosis
|
|
Osteoclast differentiation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Cytosolic DNA-sensing pathway
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
TNF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Insulin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
HTLV-I infection
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Prostate cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Small cell lung cancer
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
B cell activation
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
T cell activation
|
|
Toll receptor signaling pathway
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
GMCSF-mediated signaling events
|
|
Atypical NF-kappaB pathway
|
|
TCR signaling in naï
|
|
Canonical NF-kappaB pathway
|
|
TRAIL signaling pathway
|
|
TCR signaling in naï
|
|
FAS (CD95) signaling pathway
|
|
IL1-mediated signaling events
|
|
mTOR signaling pathway
|
|
TNF receptor signaling pathway
|
|
FoxO family signaling
|
|
p75(NTR)-mediated signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
Endogenous TLR signaling
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Reactome
|
Activation of NF-kappaB in B cells
|
|
NOD1/2 Signaling Pathway
|
|
RIP-mediated NFkB activation via ZBP1
|
|
p75NTR recruits signalling complexes
|
|
NF-kB is activated and signals survival
|
|
FCERI mediated NF-kB activation
|
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
Interleukin-1 signaling
|
|
Regulation of TNFR1 signaling
|
|
TNFR1-induced NFkappaB signaling pathway
|
|
IKBKB deficiency causes SCID
|
|
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
|
|
IkBA variant leads to EDA-ID
|
|
CLEC7A (Dectin-1) signaling
|
|
MAP3K8 (TPL2)-dependent MAPK1/3 activation
|
|
TRAF6 mediated NF-kB activation
|
|
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
|
|
IRAK1 recruits IKK complex
|
|
IKK complex recruitment mediated by RIP1
|
|
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Estrogen signaling pathway
|
|
TCR Signaling Pathway
|
|
Insulin Signaling
|
|
IL-4 Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
NLR Proteins
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
MyD88 cascade initiated on plasma membrane
|
|
Cardiac Hypertrophic Response
|
|
Cytosolic sensors of pathogen-associated DNA
|
|
MyD88 dependent cascade initiated on endosome
|
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Fc epsilon receptor (FCERI) signaling
|
|
MyD88-independent cascade
|
|
Signaling by the B Cell Receptor (BCR)
|
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
EBV LMP1 signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Apoptosis
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
BDNF signaling pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TNF alpha Signaling Pathway
|
|
B Cell Receptor Signaling Pathway
|
|
IL17 signaling pathway
|
|
TWEAK Signaling Pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Signalling by NGF
|
|
IL-1 signaling pathway
|
|
TCR signaling
|
|
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
|
|
Interleukin-1 signaling
|
|
Apoptosis Modulation and Signaling
|
|
Type II diabetes mellitus
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Regulation of toll-like receptor signaling pathway
|
|
Osteopontin Signaling
|
|
NOD pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00098956) 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 346). |
|---|
| REF 3 | UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65. |
|---|
| REF 4 | Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15. |
|---|
